470
Participants
Start Date
April 29, 2024
Primary Completion Date
April 30, 2028
Study Completion Date
December 31, 2028
Naporafenib
Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
Dacarbazine
Dacarbazine IV - Day 1
Temozolomide
Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
Trametinib
Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
RECRUITING
Sanatorium Profesora Arenbergera, Prague
RECRUITING
Calvary Mater Newcastle, Waratah
RECRUITING
Peter MacCallum Cancer Institute, Melbourne
RECRUITING
Alfred Hospital, Melbourne
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Tasman Health Care, Southport
RECRUITING
Hollywood Private Hospital, Nedlands
RECRUITING
Isala Ziekenhuis, Amsterdam
RECRUITING
APHP - Hopital Saint Louis, Paris
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de la Timone, Marseille
RECRUITING
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario Sa, Milan
RECRUITING
CHU Dijon Bourgogne - Hopital Francois Mitterand (Hopital du Bocage), Dijon
RECRUITING
Hospital General Universitario Gregorio Marañón, Madrid
RECRUITING
Hospital Universitario Ramon y Cajal, Madrid
RECRUITING
Hospital HM Sanchinarro, Madrid
ACTIVE_NOT_RECRUITING
Hospital Universitario Central de Asturias, Oviedo
RECRUITING
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre, Bordeaux
RECRUITING
Azienda Sanitaria Universitaria del Friuli Centrale, Udine
RECRUITING
University of Miami Sylvester Cancer, Miami
RECRUITING
SCRI Oncology Partners (formerly Tennessee Oncology), Nashville
RECRUITING
Cleveland Clinic Foundation, Cleveland
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
Fakultni nemocnice Hradec Kralove, Nový Hradec Králové
RECRUITING
University of Wisconsin, Madison
RECRUITING
CHRU de Lille - Hôpital Claude Huriez, Lille
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Masarykuv Onkologicky Ustav-MOU, Brno
RECRUITING
University of Kansas Cancer Center, Kansas City
RECRUITING
Centre Hospitalier Lyon-Sud, Lyon
RECRUITING
Mayo Clinic - Florida, Jacksonville
ACTIVE_NOT_RECRUITING
Ochsner Clinic Foundation, Jefferson
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Centre Hospitalier du Mans, Le Mans
RECRUITING
Hospital Ambroise Pairs, Paris
RECRUITING
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Texas Oncology- Austin Midtown, Austin
RECRUITING
The Melanoma and Skin Care Institute, Englewood
RECRUITING
The University of Utah - Huntsman Cancer Institute (HCI), Salt Lake City
RECRUITING
Mayo Clinic - Arizona, Phoenix
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
CLCC Institute Gustave Roussy, Villejuif
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Virginia Oncology Associates, Norfolk
RECRUITING
Queen Elizabeth II Health Sciences Centre, Halifax
RECRUITING
McGill University Health Centre, Montreal
RECRUITING
IRCCS Istituto Nazionale Tumori Regina Elena, Roma
RECRUITING
Istituto Dermopatico dell Immacolata IDI-IRCCS, Roma
RECRUITING
Leids Universitair Medisch Centrum, Leiden
RECRUITING
Radboud University, Nijmegen
ACTIVE_NOT_RECRUITING
Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona
RECRUITING
Hospital Clinic de Barcelona, Barcelona
RECRUITING
Royal Preston Hospital, Preston
RECRUITING
Sarah Cannon Research Institute - HCA Healthcare, City of London
RECRUITING
Royal Devon and Exeter Hospital, Exeter
ACTIVE_NOT_RECRUITING
The Royal Marsden NHS Foundation Trust, London
ACTIVE_NOT_RECRUITING
Christie Hospital, Manchester
Erasca, Inc.
INDUSTRY